UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1391-3
Program Prior Authorization/Notification
Medication Camzyos® (mavacamten)
P&T Approval Date 7/2022, 8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Camzyos® (mavacamten) is a cardiac myosin inhibitor indicated for the treatment of adults with
symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic
cardiomyopathy (HCM) to improve functional capacity and symptoms.1
2. Coverage Criteriaa:
A. Initial Authorization
1. Camzyos will be approved based on both of the following:
a. Diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
-AND-
b. Heart failure is classified as one of the following:
(1) New York Heart Association (NYHA) class II heart failure
-OR-
(2) New York Heart Association (NYHA) class III heart failure
Authorization will be issued for 12 months.
B. Reauthorization
1. Camzyos will be approved based upon the following criterion:
a. Documentation of positive clinical response to Camzyos therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and/or Medical Necessity may be in place.
4. References:
1. Camzyos® [package insert]. Brisbane, CA: Bristol Myers Squibb; April 2024.
Program Prior Authorization/Notification – Camzyos® (mavacamten)
Change Control
7/2022 New program.
8/2023 Annual review. Updated reference.
8/2024 Annual review. Added Med Nec may be in place under additional clinical
rules. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2